



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/185, 47/48, C07C 259/10		A1	(11) International Publication Number: WO 95/07076 (43) International Publication Date: 16 March 1995 (16.03.95)		
(21) International Application Number: PCT/SI94/00015		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD).			
(22) International Filing Date: 6 September 1994 (06.09.94)					
(30) Priority Data: P-9300470 10 September 1993 (10.09.93) SI					
(71) Applicant (for all designated States except US): LEK, TO- VARNA FARMACEVTSKIH IN KEMIČNIH IZDELKOV, D.D., LJUBLJANA [SI/SI]; Verovškova 57, 61107 Ljubljana (SI).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(72) Inventors; and					
(75) Inventors/Applicants (for US only): ŽMITEK, Janko [SI/SI]; Poklukarjeva 70, 61000 Ljubljana (SI). VERHNJAK, Kata- rina [SI/SI]; Polanskova 15, 61000 Ljubljana (SI). FERČEJ- TEMELJOTOV, Darja [SI/SI]; Linhartova 40, 61000 Ljubljana (SI). KOVACIČ, Mateja [SI/SI]; Prijateljeva 14, 61000 Ljubljana (SI). LAVRIČ, Anton [SI/SI]; Pavšičeva 4, 61000 Ljubljana (SI). BOLE-VUNDUK, Breda [SI/SI]; Vrtača 3, 61000 Ljubljana (SI).					
(74) Agent: PATENTNA PISARNA; Čopova 14, P.O. Box 322, 61001 Ljubljana (SI).					
(54) Title: INCLUSION COMPLEXES OF RACEMIC IBUPROXAM AND OF OPTICALLY ACTIVE IBUPROXAM WITH CYCLODEXTRIN DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE INCLUSION COMPLEXES OR CONTAINING OPTICALLY ACTIVE S-(+)-IBUPROXAM, AND USE THEREOF					
(57) Abstract					
<p>There are disclosed novel inclusion complexes of racemic ibuproxam and of optically active S-(+)-ibuproxam with hydrophilic and hydrophobic cyclodextrin derivatives and, in the case of optically active S-(+)-ibuproxam, also with β-cyclodextrin alone. Further a process for preparing S-(+)-ibuproxam and inclusion complexes of racemic ibuproxam and of optically active S-(+)-ibuproxam with hydrophilic and hydrophobic derivatives of β-cyclodextrin and, in the case of optically active S-(+)-ibuproxam, also with β-cyclodextrin alone, is disclosed. Disclosed are also pharmaceutical compositions containing these inclusion complexes or optically active S-(+)-ibuproxam. Optically active S-(+)-ibuproxam and novel inclusion complexes of racemic ibuproxam and of optically active ibuproxam with cyclodextrin derivatives and, in the case of optically active S-(+)-ibuproxam, also with β-cyclodextrin alone, are better soluble in water and have improved biopharmaceutical properties such as lesser toxicity, better antiinflammatory action and non-irritation of the gastric mucous membrane.</p>					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroun	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Inclusion Complexes of Racemic Ibuproxam and of Optically Active Ibuproxam with Cyclodextrin Derivatives, Process for the Preparation Thereof, Pharmaceutical Preparations Containing these Inclusion Complexes or Containing Optically Active S-(+)-Ibuproxam, and Use Thereof

Technical Field

(IPC A 61 K 31/185)


The present invention belongs to the field of pharmaceutical industry and relates to novel inclusion complexes of racemic ibuproxam and optically active S-(+)-ibuproxam with cyclodextrin derivatives such as methyl- β -cyclodextrin, dimethyl- β -cyclodextrin, hydroxypropyl- β -cyclodextrin, hydroxyethyl- β -cyclodextrin, triacetyl- β -cyclodextrin and, in the case of optically active S-(+)-ibuproxam, also with β -cyclodextrin. The invention also relates to a process for the preparation thereof, to pharmaceutical compositions containing these inclusion complexes or optically active S-(+)-ibuproxam, and to the use thereof in the treatment of inflammations and febrile conditions as well as in alleviating pain.

Technical Problem

There exists a constant need for preparing novel galenic forms of ibuproxam, racemic as well as optically active one, having improved biopharmaceutical properties such as low toxicity, better antiinflammatory action and non-irritation of gastric mucous membrane.

Prior Art

Ibuproxam is a generic name for 2-(4-isobutylphenyl)-propiohydroxamic acid of the formula



The substance was described for the first time in US 4,082,707 as a solid crystalline substance in the form of white shining thin platelets having analgetic, antipyretic and antiinflammatory properties. The substance is soluble in methanol, ethanol, acetone and ethyl ether and is insoluble in water and petroleum ether.

The substance is ibuprofen (2-(4-isobutylphenyl)-propionic acid) prodrug. It has been experimentally confirmed that, irrespective of the ibuproxam application route, there occurs a rapid and almost complete metabolic conversion into ibuprofen. In the article by Orzalesi G. et al., Arzneim.-Forsch./Drug Res. 30 (II), the determination of ibuproxam and ibuprofen in blood is disclosed. The presence of ibuproxam and ibuprofen in blood was measured 15 minutes after application. The value of ibuprofen was 2.5 times higher than the value of ibuproxam, thus indicating a high rate of the conversion of ibuproxam into ibuprofen. In the article by Orzalesi G. et al., Arzneim.-Forsch./Drug Res. 27 (I) there are disclosed comparisons between the properties of ibuprofen and ibuproxam evidencing the same analgetic, antipyretic and antiinflammatory action of both substances. The introduction of hydroxylamine radical into the ibuprofen molecule increases the tolerance of the molecule, which is especially the result of different pharmakinetics of ibuproxam. The latter is less toxic for the mucous membrane of the alimentary tract with the result that the by-effects and toxicity of the active substance are essentially reduced. Simultaneously, the chemical conversion of ibuprofen into ibuproxam makes possible an increase of the transfer rate and an increase of ibuprofen concentration in blood in comparison with ibuprofen. The better bioavailability of ibuproxam in comparison with ibuprofen is the result of different physicochemical properties of either substance. In the same article a comparison between parenteral and peroral application of ibuprofen and ibuproxam is also disclosed. At parenteral application LD₅₀ is the same for both substances, whereas LD₅₀ at peroral application of ibuproxam is twice to three times greater than that of ibuprofen.

It is well-known that several biologically active substances exist in the form of a stereoisomeric mixture whereas usually only one isomer is biologically active. It has been proven that only S-(+)-enantiomer of ibuprofen is pharmacologically active. In the body of mammals (in liver and kidneys) R-(-)-enantiomer is to a varying extent converted by means of metabolic stereoisomeric inversion into the active form of S-(+)-ibuprofen (Ching-Shih C. et al., *Biochimica et Biophysica Acta*, 1078 (1991)). According to data from the article by Geisslinger G. et al., *Agents and Actions*, Vol. 27, 3/4 (1989), in humans only R-(-)-enantiomer, yet only one third thereof, is converted to S-(+)-enantiomer.

In the literature there are disclosed several advantages of S-(+)-ibuprofen over racemic ibuprofen. From EP-B1-267 321 there are known sustained-release medicaments in the form of tablets or capsules containing ibuprofen only in the optically active form. In WO 89/00421 methods for increasing analgetic response in the organisms of mammals by means S-(+)-enantiomer of ibuprofen are disclosed. A pharmaceutical preparation for the treatment of fever and inflammations and for alleviating pain, said preparation containing S-(+)-ibuprofen sodium salt, is disclosed in WO 92/20334. In US 5,100,918 a method for the treatment of sunburns with S-(+)-ibuprofen is disclosed.

Combinations of optically active ibuprofen with other optically active substances are disclosed as well. Thus in WO 92/05783 there is disclosed a combination with antihistaminics, in WO 92/17177 a combination with antitussives and expectorants and in WO 92/17171 a combination with sympathomimetics.

Ibuprofen as well as ibuproxam are very poorly soluble in water, which affects the rate and extent of absorption from the gastrointestinal tract and the bioavailability after peroral application.

Inclusion complexes with cyclodextrins are known from numerous literature sources such as J. Szejtli, *Cyclodextrins and their Inclusion Complexes*, Akademiai Kiado, Budapest, 1982, and J. Szejtly, *Cyclodextrin Technology*, Kluwer Academic Publishers, 1988. Cyclodextrins are cyclic compounds comprising 6, 7 or 8 glucopyranose units bound with α -1,4-glycosidic bonds. They are characterized by a cylindrical structure and special arrangement of hydroxylic groups, the outer surface of cyclodextrin ring being hydrophilic, which ensures water solubility, whereas its interior surface is lipophilic, which allows other molecules known as "guest molecules" or parts thereof

that are less polar than water (hydrofobic molecules) and are of suitable dimensions, to be bound into the lipophilic cavity in the interior of the cylindrical cyclodextrin molecule and to form an inclusion complex.

An inclusion complex of S-(+)-ibuprofen with cyclodextrin and/or its derivatives, a process for the preparation thereof and its use in pharmaceutical formulations are disclosed in WO 92/09308. For ibuprofen bound into a complex with cyclodextrin, there are given better dissolution characteristics, a reduced offensive smell, taste and effect to the mucous membrane as well as better bioavailability.

The advantages of binding substances into inclusion complexes with cyclodextrin are also known in other active substances. Thus in US 4,603,123 an inclusion complex of piroxicam with β -cyclodextrin and advantages thereof are disclosed: a four times greater solubility, increased therapeutic activity together with a lesser effect upon the gastric mucous membrane, a greater therapeutic index, the level of the active substance in plasma is higher and it appears soon after application. In US 5,079,237 an inclusion complex of nicardipine or of its salt with β -cyclodextrin is disclosed. There are stated better characteristics of the rate and extent of dissolution and a twice better bioavailability whereas no difference in toxicity between nicardipine hydrochloride bound into a complex and free nicardipine hydrochloride can be noticed.


The inclusion complex of racemic ibuprofam with β -cyclodextrin is disclosed in US 4,952,565, wherein essential physicochemical and pharmacokinetic properties of the complex of ibuprofam with β -cyclodextrin in comparison to non-complexed ibuprofam are stated: by binding ibuprofam into the cyclodextrin molecule the solubility in water is significantly increased, the inclusion complex is less toxic than ibuprofam alone, the complexing significantly increases the dissolution rate, the absorption constant of the complex is greater than the constant of the commercial preparation - tablets Ibudros®, the relative bioavailability of the complex is 100% greater than that of the standard tablet preparation Ibudros®, statistically significant differences are demonstrated with regard to the time periods necessary for the achievement of maximum concentrations and to average plasma concentrations, the same activity being achieved by half a dose of ibuprofam.

Technical Solution

The problem to be solved by the present invention is to convert the racemic ibuproxam and optically active S-(+)-ibuproxam into a form better soluble in water, which would make possible the preparation of galenic forms having improved pharmacological properties. The object of the invention was especially to prepare inclusion complexes of β -cyclodextrin derivatives with optically active S-(+)-ibuproxam of high purity as well as to prepare S-(+)-ibuproxam, all of them having lower toxicity, better antiinflammatory action and better water solubility than the free racemic form of ibuproxam.

This object is achieved by binding racemic ibuproxam and optically active S-(+)-ibuproxam into the structure of derivatives of cyclodextrin molecules. Thus novel inclusion complexes in the form of a white powder are obtained.

The first object of the invention is thus an inclusion complex of racemic 2-(4-isobutylphenyl)-propiohydroxamic acid and of optically active S-(+)-2-(4-isobutylphenyl)-propiohydroxamic acid (ibuproxam) of the formula



with cyclodextrin derivatives and, in the case of optically active S-(+)-2-(4-isobutylphenyl)-propiohydroxamic acid, also with β -cyclodextrin alone.

For the preparation of the inventive inclusion complexes α -cyclodextrin, β -cyclodextrin and γ -cyclodextrin, preferably β -cyclodextrin, and their hydrophilic and hydrophobic derivatives may be used. As hydrophilic cyclodextrin derivatives all such known compounds may be used such as hexakis-(2,3,6-tri-O-methyl)- α -cyclodextrin (abbr. TRIMEA), heptakis-(2,6-di-O-methyl)- β -cyclodextrin (abbr. DIMEB), monomethyl- β -cyclodextrin, methyl- β -cyclodextrin (abbr. RAMEB), heptakis-(2,3,6-tri-O-methyl)- β -cyclodextrin (abbr. TRIMEB), hydroxyethyl- β -cyclodextrin, hydroxypropyl- β -cyclodextrin, branched β -cyclodextrin derivatives such as glucosyl- β -cyclodextrin, dimaltosyl- β -cyclodextrin, diglucosyl- β -cyclodextrin, succinyl- β -cyclodextrin, and the like.

dextrin and others. As hydrophobic β -cyclodextrin derivatives all such known compounds may be used such as heptakis-(2,3,6-tri-O-acetyl)- β -cyclodextrin (abbr. triacetyl- β -CD), heptakis-(2,6-di-O-ethyl)- β -cyclodextrin (abbr. DE- β -CD), heptakis-(2,3-di-O-ethyl)- β -cyclodextrin, heptakis-(2,3,6-tri-O-ethyl)- β -cyclodextrin (abbr. TE- β -CD), O-carboxymethyl-O-ethyl- β -cyclodextrin, heptakis-2,6-di-O-pentyl- β -cyclodextrin, heptakis-2,3,6-tri-O-pentyl- β -cyclodextrin, heptakis-(3-O-acetyl-2,6-di-O-pentyl)- β -cyclodextrin and others.

Further, for the preparation of the inclusion complexes there can be used hydrophilic dihydroxyalkyl polymer derivatives of cyclodextrin, which are cyclodextrin polymers, or ionic cyclodextrin polymers such as aminoalkyl(C_1 - C_3)-, or dialkyl(C_1 - C_3)-aminoalkyl(C_1 - C_3)-substituted polymers.

Inclusion complexes of racemic ibuproxam and of optically active S-(+)-ibuproxam with β -cyclodextrin derivatives and, in the case of optically active S-(+)-ibuproxam, also with β -cyclodextrin alone are novel compounds hitherto not disclosed in the literature.

Optically active S-(+)-ibuproxam of high purity was prepared from commercial S-(+)-ibuprofen of 99.4% purity (Ethyl Corporation) in such a way that at first in methanol at the temperature of about 30 °C S-(+)-ibuprofen methyl ester was prepared, which was then converted with hydroxylamine hydrochloride at the temperature of about 0 °C into S-(+)-ibuproxam. The percentage of optical purity did not change during the reaction so that for preparing inclusion complexes with β -cyclodextrin and with derivatives thereof 99.4% S-(+)-ibuproxam was used.

The above process is also an object of the present invention.

Optically active S-(+)-ibuproxam of high purity could also be prepared from the commercial S-(+)-ibuprofen of 99.4% purity (Ethyl Corporation) in such a way that S-(+)-ibuprofen was converted in an organic solvent into S-(+)-ibuprofen anhydride (bis-[2-(4-isobutylphenyl)-propionic acid]-anhydride) at a temperature of about 30 °C according to the process disclosed in EP-A-0203379, which anhydride was then at the room temperature converted with hydroxylamine in an organic solvent such as e.g. dichloromethane, chloroform and acetonitrile, into S-(+)-ibuproxam. Also in this reaction the percentage of the optical purity did not change.

The above process is also an object of the present invention.

Inclusion complex of optically active S-(+)-ibuproxam with β -cyclodextrin was prepared in such a way that into a boiling β -cyclodextrin aqueous solution S-(+)-ibuproxam was added and after the completed reaction the undissolved ibuproxam was filtered off, the filtrate was cooled and the complex so formed was isolated. The reaction could also take place in an aqueous-methanolic medium instead in an aqueous medium, wherein β -cyclodextrin was dissolved in water at a temperature of about 70 °C, methanolic solution of S-(+)-ibuproxam was added and after the completed reaction the solvent was evaporated and then the inclusion complex formed was isolated and dried *in vacuo* at the temperature of 40 °C.

The above process is also an object of the present invention.

Inclusion complexes of racemic ibuproxam and optically active S-(+)-ibuproxam with hydrophilic derivatives of β -cyclodextrin were prepared in such a way that to an alcoholic solution such as e.g. methanolic solution of the hydrophilic derivative of β -cyclodextrin at room temperature, racemic ibuproxam or its S-(+)-enantiomer was added and after the completed reaction the obtained inclusion complex was isolated. The reaction could also take place in an aqueous medium, whereat the hydrophilic derivative of β -cyclodextrin was dissolved in water, the solution was heated to a temperature of about 70 °C, racemic ibuproxam or its S-(+)-enantiomer was added and it was vigorously stirred. The obtained solution was frozen in liquid nitrogen and lyophilized.

The above process is also an object of the present invention.

The inclusion complexes of racemic ibuproxam and optically active S-(+)-ibuproxam with hydrophobic derivatives of β -cyclodextrin were prepared in such a way that a hydrophobic derivative of β -cyclodextrin was dissolved in an organic solvent and then racemic or optically active ibuproxam was added while stirring at room temperature. After the completed stirring the obtained clear solution was evaporated *in vacuo* at the temperature of 40 °C and the residue was isolated and dried in a vacuum drier at room temperature to the desired oily product. As the organic solvent acetone, ethyl acetate, dichloromethane, chloroform and other solvents could be used. Also a mixture of an organic solvent with water (e.g. acetone/water mixture) could be used. In this case a hydrophobic derivative of β -cyclodextrin was dissolved in the organic sol-

vent at a temperature of about 40 °C and then there were added racemic or optically active ibuproxam and more water under vigorous stirring. The obtained solution was cooled to a temperature between 0 and 5 °C. The formed precipitate was filtered off and dried *in vacuo* at the temperature of 40 °C.

The above process is also an object of the present invention.

The yield in both cases, for inclusion complexes of β -cyclodextrin derivatives with racemic as well as with optically active ibuproxam, was high i.e. over 94%.

Inclusion complexes of racemic and optically active ibuproxam with β -cyclodextrin derivatives and, in the case of optically active S-(+)-ibuproxam, also with β -cyclodextrin alone could be formed in a ratio of 1:5 to 5:1, preferably in a ratio of 1:2 to 2:1.

The present invention also relates to pharmaceutical preparations containing a therapeutically active amount of inclusion complexes of racemic ibuproxam or optically active S-(+)-ibuproxam with cyclodextrin derivatives, in the case of optically active S-(+)-ibuproxam, also with β -cyclodextrin alone, together with a conventional pharmaceutically acceptable carrier and other adjuvants. To provide a systemic action of ibuproxam the following application routes are possible: peroral, rectal, transnasal, transbuccal, transdermal, and parenteral application, in an adequate pharmaceutical form such as tablets, capsules, drageés, and in forms such as sustained-release forms, effervescent forms, dispersion forms, gastroresistant forms, syrups, suspensions, solutions, suppositories, ointments, gels, emulsions, injections, infusions etc. Tablets may also be lacquered, whereat the usual process for applying a lacquer coating onto the tablet surface by means of the spraying method is used. To provide a topical action of ibuproxam the following application routes are possible: dermal, ocular, vaginal application, in an adequate pharmaceutical form such as cremes, ointments, gels, solutions and suspensions, eye ointments, eye drops, vagitories etc. In addition to the active substance, these preparations also contain pharmaceutically acceptable adjuvants in their optimum concentrations such as carriers, stabilizers, preservatives, colourants etc. The preparations are prepared according to known methods specific for a certain pharmaceutical form.

The present invention further relates to pharmaceutical preparations containing a therapeutically active amount of the optically active S-(+)-ibuproxam together with a conventional pharmaceutically acceptable carrier and other adjuvants.

The present invention also relates to the use of optically active S-(+)-ibuproxam and novel inclusion complexes of racemic ibuproxam and of optically active S-(+)-ibuproxam with cyclodextrin derivatives and, in the case of optically active S-(+)-ibuproxam, with β -cyclodextrin alone as a medicine as well as to their use in the treatment of inflammations and febrile conditions and for alleviating pain.

The invention is illustrated by the following Examples which in no way represent a limitation thereof.

Example 1

Preparation of S-(+)-ibuproxam

Optically active S-(+)-ibuproxam may be prepared in two ways:

a) S-(+)-ibuprofen (5.0 g; 0.024 mole) was shed into methanol (35 ml), concentrated sulfuric acid (1 ml) was added and the reaction mixture was heated for 3 hours at the reflux temperature of the reaction mixture. Then it was evaporated *in vacuo* at the temperature of 30 °C to dryness. S-(+)-ibuprofen methyl ester (5.1 g) was obtained.

Hydroxylamine hydrochloride (1.7 g; 0.024 mole) was poured over with methanol (38 ml) and cooled to the temperature of 0 °C. A methanolic solution (13 ml) of sodium hydroxide (4.7 g of NaOH/13 ml of methanol) and S-(+)-ibuprofen methylester (5.1 g) were slowly added and it was stirred for 4 hours at the temperature of 20 °C. The reaction mixture was evaporated *in vacuo* at the temperature of 30 °C to dryness. Then demineralized water (70 ml) was added. The reaction mixture was neutralized with a hydrochloric acid aqueous solution (20%) up to the pH value of 6. The product was filtered off and the filtrate was dried *in vacuo* at a temperature up to 30 °C. The product was crystallized first from a methanol/water mixture and then from a petroleum ether/acetone mixture. There was obtained S-(+)-ibuproxam (4.5 g) in the form of a white powder, m.p. 119 to 121 °C.

b) S-(+)-ibuprofen (2.3 g; 0.011 mole) was dissolved in dichloromethane (15 ml) and then N,N'-dicyclohexylcarbodiimide (DCC) (1.15 g) was added. The reaction mixture was stirred for 1 hour at the temperature of 30 °C, then filtered and the filtrate was evaporated *in vacuo*. S-(+)-ibuprofen anhydride (2.19 g; 100%) was obtained in the form of an oily product.

S-(+)-ibuprofen anhydride (2 g; 0.005 mole) was dissolved in dichloromethane (10 ml) and hydroxylamine (0.18 g; 0.0055 mole) was added. The reaction mixture was stirred for 1 hour at room temperature, then the solvent was evaporated *in vacuo*, the residue was poured over with petroleum ether (15 ml) and stirred for two hours. The obtained product was filtered off and washed with petroleum ether. S-(+)-ibuproxam (1.13 g; 92%) was obtained in the form of a white powder, m.p. 119 to 121 °C.

Specific rotation:

$$[\alpha]^{23}_{\text{Na}} \text{ (ethanol abs., 0.30)} = +44.4^\circ$$

IR and NMR spectra of S-(+)-ibuproxam corresponded to the spectra of racemic ibuproxam.

Fig. 1 shows IR spectrum of racemic ibuproxam and S-(+)-ibuproxam.

Figs. 2A and 2B show NMR spectrum of racemic ibuproxam and S-(+)-ibuproxam.

Fig. 3 shows DSC (differential scanning calorimetry) thermogram of racemic ibuproxam and S-(+)-ibuproxam.

Example 2

Preparation of inclusion complex of optically active S-(+)-ibuproxam with β -cyclodextrin

a) Procedure in aqueous medium

β -cyclodextrin (1.135 g; 1.0 mmole) in water (10 ml) was heated to boiling temperature. Into the boiling solution S-(+)-ibuproxam (0.221 g; 1.0 mmole) was added and it was vigorously stirred for 2 minutes. Undissolved S-(+)-ibuproxam was filtered off and the filtrate was cooled during stirring to a temperature between 0 and 5 °C. The obtained complex was filtered off by suction and dried *in vacuo* at the temperature of about 40 °C. Inclusion complex (1.28 g; 94.4%) of S-(+)-ibuproxam with β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Data on reaction yields, ibuproxam content in the complex (determined theoretically and experimentally - spectrophotometric determination at the wavelength of 220 nm) and specific rotation $[\alpha]^{23}_{\text{Na}}$ of the complex formed are summarized in Table 2.

Differential scanning calorimetry (DSC thermogram):

In the curve of the obtained product there was not detected any endothermic transition for a melting point, characteristic of a physical mixture of ibuproxam/ β -cyclodextrin at a temperature from 120 to 130 °C (Figs. 4A and 4B).

NMR spectrum:

In the $^1\text{H-NMR}$ spectrum of the title complex in DMSO-D_6 solution the following change in the ibuproxam moiety was observed: at 7.19-7.25 ppm the signal for proton resonances in phenyl ring shifted to a higher field.

Fig. 5 shows NMR spectrum of the complex of S-(+)-ibuproxam with β -cyclodextrin.

b) Procedure in a solvent mixture (methanol/water in the ratio 5:20)

β -cyclodextrin (1.135 g; 1.0 mmole) was dissolved in water (20 ml) at a temperature of about 70 °C. During stirring a solution of S-(+)-ibuproxam (0.221 g; 1.0 mmole) in methanol (5 ml) was added. At the temperature of 70 °C it was stirred for another 5 minutes, when the solvents were evaporated. The obtained complex was dried *in vacuo* at a temperature about 40 °C. Inclusion complex (1.26 g; 92.9%) of S-(+)-ibuproxam with β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Differential scanning calorimetry and NMR spectrum showed the same results as in the process for preparing the inclusion complex in an aqueous medium.

Example 3**Preparation of inclusion complex of racemic ibuproxam with methyl- β -cyclodextrin****a) Procedure in methanolic medium**

Racemic ibuproxam (0.221 g; 1.0 mmole) was added to a solution of methyl- β -cyclodextrin (1.31 g; 1.0 mmole) in methanol (10 ml). The obtained solution was stirred for another 5 minutes at room temperature. Methanol was then evaporated and the obtained complex was dried *in vacuo* at the temperature of 40 °C. Inclusion complex (1.51 g; 98.6%) of racemic ibuproxam with methyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Data on reaction yields, ibuproxam content in the complex (determined theoretically and experimentally - spectrophotometric determination at the wavelength of 220 nm) and specific rotation $[\alpha]^{23}_{\text{Na}}$ of the complex formed are summarized in Table 1.

Differential scanning calorimetry (DSC thermogram):

In the curve of the obtained product there was not detected any endothermic transition for a melting point, characteristic of a physical mixture of ibuproxam/methyl- β -cyclodextrin at a temperature from 120 to 130 °C (Figs. 6A and 6B).

NMR spectrum:

In the $^1\text{H-NMR}$ spectrum of the title complex in DMSO-D_6 solution the following change in the ibuproxam moiety was observed: at 7.19-7.25 ppm the signal for proton resonances in phenyl ring shifted to a higher field.

Fig. 7 shows NMR spectrum of the complex of racemic ibuproxam with methyl- β -cyclodextrin.

b) Procedure in aqueous medium

Methyl- β -cyclodextrin (1.31 g; 1.0 mmole) was dissolved in water (10 ml). The obtained solution was heated to the temperature of 70 °C and racemic ibuproxam (0.221 g; 1.0 mmole) was added. It was vigorously stirred for another 5 minutes. The solution was frozen in liquid nitrogen and lyophilized. Inclusion complex (1.48 g; 96.7%) of racemic ibuproxam with methyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Differential scanning calorimetry and NMR spectrum showed the same results as in the process for preparing inclusion complex in the methanolic medium.

Example 4**Preparation of inclusion complex of S-(+)-ibuproxam with methyl- β -cyclodextrin****a) Procedure in methanolic medium**

S-(+)-ibuproxam (0.221 g; 1.0 mmole) was added to a solution of methyl- β -cyclodextrin (1.31 g; 1.0 mmole) in methanol (10 ml). The obtained solution was stirred for another 5 minutes at room temperature. Methanol was then evaporated and the obtained complex was dried *in vacuo* at the temperature of 40 °C. Inclusion complex (1.51 g; 98.6%) of S-(+)-ibuproxam with methyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Data on reaction yields, ibuproxam content in the complex (determined theoretically and experimentally - spectrophotometric determination at the wavelength of 220 nm) and specific rotation $[\alpha]^{23}_{\text{Na}}$ of the complex formed are summarized in Table 2.

Differential scanning calorimetry (DSC thermogram):

In the curve of the obtained product there was not detected any endothermic transition for a melting point, characteristic of a physical mixture of ibuproxam/methyl- β -cyclodextrin at a temperature from 120 to 130 °C (Figs. 8A and 8B).

NMR spectrum:

In the $^1\text{H-NMR}$ spectrum of the title complex in DMSO-D_6 solution the following change in the ibuproxam moiety was observed: at 7.19-7.25 ppm the signal for proton resonances in phenyl ring shifted to a higher field.

Fig. 9 shows NMR spectrum of the complex of S-(+)-ibuproxam with methyl- β -cyclodextrin.

b) Procedure in aqueous medium

Methyl- β -cyclodextrin (1.31 g; 1.0 mmole) was dissolved in water (30 ml). The obtained solution was heated to the temperature of 70 °C and S-(+)-ibuproxam (0.221 g; 1.0 mmole) was added and it was vigorously stirred for another 15 minutes. The solution was frozen in liquid nitrogen and lyophilized. Inclusion complex (1.33 g; 86.9%) of S-(+)-ibuproxam with methyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Differential scanning calorimetry and NMR spectrum showed the same results as in the process for preparing inclusion complex in the methanolic medium.

Example 5

Preparation of inclusion complex of racemic ibuproxam with hydroxypropyl- β -cyclodextrin

a) Procedure in methanolic medium

Racemic ibuproxam (0.221 g; 1.0 mmole) was added to a solution of hydroxypropyl- β -cyclodextrin (1.38 g; 1.0 mmole) in methanol (10 ml) and the obtained solution was stirred for another 5 minutes at room temperature. Methanol was then evaporated and the obtained complex was dried *in vacuo* at the temperature of 40 °C. Inclusion complex (1.57 g; 98.1%) of racemic ibuproxam with hydroxypropyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Data on reaction yields, ibuproxam content in the complex (determined theoretically and experimentally - spectrophotometric determination at the wavelength of 220 nm) and specific rotation $[\alpha]^{23}_{\text{Na}}$ of the complex formed are summarized in Table 1.

Differential scanning calorimetry (DSC thermogram):

In the curve of the obtained product there was not detected any endothermic transition for a melting point, characteristic of a physical mixture of ibuproxam/hydroxypropyl- β -cyclodextrin at a temperature from 120 to 130 °C (Figs. 10A and 10B).

NMR spectrum:

In the $^1\text{H-NMR}$ spectrum of the title complex in DMSO-D_6 solution the following change in the ibuproxam moiety was observed: at 7.19-7.25 ppm the signal for proton resonances in phenyl ring shifted to a higher field.

Fig. 11 shows NMR spectrum of the complex of racemic ibuproxam with hydroxypropyl- β -cyclodextrin.

b) Procedure in aqueous medium

Hydroxypropyl- β -cyclodextrin (1.38 g; 1.0 mmole) was dissolved in water (40 ml) and the obtained solution was heated to the temperature of 70 °C and racemic ibuproxam (0.221 g; 1.0 mmole) was added. It was vigorously stirred for another 15 minutes and then the solution was filtered. The filtrate was frozen in liquid nitrogen and lyophilized. Inclusion complex (1.40 g; 87.4%) of racemic ibuproxam with hydroxypropyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Differential scanning calorimetry and NMR spectrum showed the same results as in the process for preparing inclusion complex in the methanolic medium.

Example 6

Preparation of inclusion complex of S-(+)-ibuproxam with hydroxypropyl- β -cyclodextrin

a) Procedure in methanolic medium

S-(+)-ibuproxam (0.221 g; 1.0 mmole) was added to a solution of hydroxypropyl- β -cyclodextrin (1.38 g; 1.0 mmole) in methanol (10 ml) and the obtained solution was stirred for another 5 minutes at room temperature. Methanol was then evaporated and the obtained complex was dried *in vacuo* at the temperature of 40 °C. Inclusion complex (1.56 g; 97.4%) of S-(+)-ibuproxam with hydroxypropyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Data on reaction yields, ibuproxam content in the complex (determined theoretically and experimentally - spectrophotometric determination at the wavelength of 220 nm) and specific rotation $[\alpha]^{23}_{\text{Na}}$ of the complex formed are summarized in Table 2.

Differential scanning calorimetry (DSC thermogram):

In the curve of the obtained product there was detected no endothermic transition for a melting point, characteristic of a physical mixture of ibuproxam/hydroxypropyl- β -cyclodextrin at a temperature from 120 to 130 °C (Figs. 12A and 12B).

NMR spectrum:

In the $^1\text{H-NMR}$ spectrum of the title complex in DMSO-D_6 solution the following change in the ibuproxam moiety was observed: at 7.19-7.25 ppm the signal for proton resonances in phenyl ring shifted to a higher field.

Fig. 13 shows NMR spectrum of the complex of S-(+)-ibuproxam with hydroxypropyl- β -cyclodextrin.

b) Procedure in aqueous medium

Hydroxypropyl- β -cyclodextrin (1.38 g; 1.0 mmole) was dissolved in water (40 ml). The obtained solution was heated to the temperature of 70 °C and S-(+)-ibuproxam (0.221 g; 1.0 mmole) was added. It was vigorously stirred for another 15 minutes and

the solution was filtered. The filtrate was frozen in liquid nitrogen and lyophilized. Inclusion complex (1.49 g; 93.1%) of S-(+)-ibuproxam with hydroxypropyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Differential scanning calorimetry and NMR spectrum showed the same results as in the process for preparing inclusion complex in the methanolic medium.

Example 7

Preparation of inclusion complex of racemic ibuproxam with hydroxyethyl- β -cyclodextrin

a) Procedure in methanolic medium

Racemic ibuproxam (0.221 g; 1.0 mmole) was added to a solution of hydroxyethyl- β -cyclodextrin (1.44 g; 1.0 mmole) in methanol (10 ml) and the obtained solution was stirred for another 5 minutes at room temperature. Methanol was then evaporated and the obtained complex was dried *in vacuo* at the temperature of 40 °C. Inclusion complex (1.58 g; 95.1%) of racemic ibuproxam with hydroxyethyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Data on reaction yields, ibuproxam content in the complex (determined theoretically and experimentally - spectrophotometric determination at the wavelength of 220 nm) and specific rotation $[\alpha]^{23}_{\text{Na}}$ of the complex formed are summarized in Table 1.

Differential scanning calorimetry (DSC thermogram):

In the curve of the obtained product there was not detected any endothermic transition for a melting point, characteristic of a physical mixture of ibuproxam/hydroxyethyl- β -cyclodextrin at a temperature from 120 to 130 °C (Figs. 14A and 14B).

NMR spectrum:

In the $^1\text{H-NMR}$ spectrum of the title complex in DMSO-D_6 solution the following change in the ibuproxam moiety was observed: at 7.19-7.25 ppm the signal for proton resonances in phenyl ring shifted to a higher field.

Fig. 15 shows NMR spectrum of the complex of racemic ibuproxam with hydroxyethyl- β -cyclodextrin.

b) Procedure in aqueous medium

Hydroxyethyl- β -cyclodextrin (1.44 g; 1.0 mmole) was dissolved in water (40 ml). The obtained solution was heated to the temperature of 70 °C and racemic ibuproxam (0.221 g; 1.0 mmole) was added. It was vigorously stirred for another 15 minutes and then the solution was filtered. The filtrate was frozen in liquid nitrogen and lyophilized. Inclusion complex (1.53 g; 92.1%) of racemic ibuproxam with hydroxyethyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Differential scanning calorimetry and NMR spectrum showed the same results as in the process for preparing inclusion complex in the methanolic medium.

Example 8

Preparation of inclusion complex of S-(+)-ibuproxam with hydroxyethyl- β -cyclodextrin

a) Procedure in methanolic medium

S-(+)-ibuproxam (0.221 g; 1.0 mmole) was added to a solution of hydroxyethyl- β -cyclodextrin (1.44 g; 1.0 mmole) in methanol (10 ml) and the obtained solution was stirred for another 5 minutes at room temperature. Methanol was then evaporated and the obtained complex was dried *in vacuo* at the temperature of 40 °C. Inclusion complex (1.57 g; 94.5%) of S-(+)-ibuproxam with hydroxyethyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Data on reaction yields, ibuproxam content in the complex (determined theoretically and experimentally - spectrophotometric determination at the wavelength of 220 nm) and specific rotation $[\alpha]^{23}_{\text{Na}}$ of the complex formed are summarized in Table 2.

Differential scanning calorimetry (DSC thermogram):

In the curve of the obtained product there was not detected any endothermic transition for a melting point, characteristic of a physical mixture of ibuproxam/

hydroxyethyl- β -cyclodextrin at a temperature from 120 to 130 °C (Figs. 16A and 16B).

NMR spectrum:

In the $^1\text{H-NMR}$ spectrum of the title complex in DMSO-D_6 solution the following change in the ibuproxam moiety was observed: at 7.19-7.25 ppm the signal for proton resonances in phenyl ring shifted to a higher field.

Fig. 17 shows NMR spectrum of the complex of S-(+)-ibuproxam with hydroxyethyl- β -cyclodextrin.

b) Procedure in aqueous medium

Hydroxyethyl- β -cyclodextrin (1.44 g; 1.0 mmole) was dissolved in water (40 ml). The obtained solution was heated to the temperature of 70 °C and S-(+)-ibuproxam (0.221 g; 1.0 mmole) was added. It was vigorously stirred for another 15 minutes and the solution was filtered. The filtrate was frozen in liquid nitrogen and lyophilized. Inclusion complex (1.52 g; 91.5%) of S-(+)-ibuproxam with hydroxyethyl- β -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Differential scanning calorimetry and NMR spectrum showed the same results as in the process for preparing inclusion complex in the methanolic medium.

Example 9

Preparation of inclusion complex of racemic ibuproxam with triacetyl- β -cyclodextrin

a) Procedure in organic solvent

Triacetyl- β -cyclodextrin (2.018 g; 1.0 mmole) was dissolved in acetone (10 ml) and to the solution racemic ibuproxam (0.221 g; 1.0 mmole) was added during stirring at room temperature. It was stirred for another 5 minutes, then the clear solution was evaporated *in vacuo* at the temperature of 40 °C and the residue was dried in a vacuum drier at room temperature to the dry product. The title complex (2.23 g; 99.6%) was obtained in the form of a white powder in the molar ratio of 1:1, containing ibuproxam (9.6%).

Data on reaction yields, ibuproxam content in the complex (determined theoretically and experimentally - spectrophotometric determination at the wavelength of 220 nm) and specific rotation $[\alpha]^{23}_{\text{Na}}$ of the complex formed are summarized in Table 1.

Differential scanning calorimetry (DSC thermogram):

In the curve of the obtained product there was not detected any endothermic transition for a melting point, characteristic of a physical mixture of ibuproxam/triacetyl- β -cyclodextrin at a temperature from 120 to 130 °C (Figs. 18A and 18B).

NMR spectrum:

In the $^1\text{H-NMR}$ spectrum of the title complex in DMSO-D_6 solution the following change in the ibuproxam moiety was observed: at 7.19-7.25 ppm the signal for proton resonances in phenyl ring shifted to a higher field.

Fig. 19 shows NMR spectrum of the complex of racemic ibuproxam with triacetyl- β -cyclodextrin.

b) Procedure in solvent mixture (acetone/water in the ratio 1:1)

Triacetyl- β -cyclodextrin (2.018 g; 1.0 mmole) was dissolved in acetone (3 ml) at the temperature of 40 °C and then to the obtained solution racemic ibuproxam (0.221 g; 1.0 mmole) was added under stirring. To the obtained clear solution water (5 ml) was added under vigorous stirring, it was cooled to a temperature from 0 to 5 °C and the formed precipitate was filtered off, dried *in vacuo* at the temperature of 40 °C and the title complex was obtained.

Differential scanning calorimetry and NMR spectrum showed the same results as in the process for preparing inclusion complex in organic solvent.

Example 10

Preparation of inclusion complex of S-(+)-ibuproxam with triacetyl- β -cyclodextrin

a) Procedure in organic solvent

Triacetyl- β -cyclodextrin (2.018 g; 1.0 mmole) was dissolved in acetone (10 ml) and to the solution S-(+)-ibuproxam (0.221 g; 1.0 mmole) was added during stirring at room

temperature. It was stirred for another 5 minutes, then the clear solution was evaporated *in vacuo* at the temperature of 40 °C and the residue was dried in a vacuum drier at room temperature to the dry product. The title complex (2.22 g; 99.2%) was obtained in the form of a white powder in the molar ratio of 1:1, containing S-(+)-ibuproxam (9.8%).

Data on reaction yields, ibuproxam content in the complex (determined theoretically and experimentally - spectrophotometric determination at the wavelength of 220 nm) and specific rotation $[\alpha]^{23}_{\text{Na}}$ of the complex formed are summarized in Table 2.

Differential scanning calorimetry (DSC thermogram):

In the curve of the obtained product there was detected no endothermic transition for a melting point, characteristic of a physical mixture of ibuproxam/triacetyl- β -cyclodextrin at a temperature from 120 to 130 °C (Figs. 20A and 20B).

NMR spectrum:

In the $^1\text{H-NMR}$ spectrum of the title complex in DMSO-D_6 solution the following change in the ibuproxam moiety was observed: at 7.19-7.25 ppm the signal for proton resonances in phenyl ring shifted to a higher field.

Fig. 21 shows NMR spectrum of the complex of S-(+)-ibuproxam with triacetyl- β -cyclodextrin.

b) Procedure in solvent mixture (acetone/water in the ratio 1:1)

Triacetyl- β -cyclodextrin (2.018 g; 1.0 mmole) was dissolved in acetone (3 ml) at the temperature of 40 °C and then to the solution S-(+)-ibuproxam (0.221 g; 1.0 mmole) was added under stirring. To the clear solution water (5 ml) was added under vigorous stirring, it was cooled to a temperature from 0 to 5 °C. The formed precipitate was filtered off and dried *in vacuo* at the temperature of 40 °C to obtain the title complex.

Differential scanning calorimetry and NMR spectrum showed the same results as in the process for preparing inclusion complex in organic solvent.

TABLE 1

Reaction yield, ibuproxam content in the complex and specific rotation for inclusion complex of racemic ibuproxam with different derivatives of β -cyclodextrins in the ratio 1:1. Procedure in methanolic medium except for triacetyl- β -cyclodextrin where the results are summarized from the procedure in acetone.

Inclusion complex of racemic ibuproxam with	reaction yield (%)	theor. cont. (%) *	exper. cont. (%) **	spec. rotation
methyl- β -cyclodextrin	98.6	14.5	14.4	+127.8° (ethanol abs., 0.30)
hydroxyethyl- β -cyclodextrin	95.1	13.3	13.2	+108.7° (ethanol abs., 0.30)
hydroxypropyl- β -cyclodextrin	98.1	13.8	13.6	+103.1° (ethanol abs., 0.30)
triacetyl- β -cyclodextrin	99.6	9.9	9.6	+109.5° (ethanol abs., 0.30)

* theoretical content of ibuproxam in the complex

** experimentally determined content of ibuproxam in the complex

TABLE 2

Reaction yield, ibuproxam content in the complex and specific rotation for inclusion complex of S-(+)-ibuproxam with different derivatives of β -cyclodextrins in the ratio 1:1, Procedure in methanolic medium except for β -cyclodextrin where the medium is water, and for triacetyl- β -cyclodextrin where the medium is acetone

Inclusion complex of S-(+)- ibuproxam with	reaction yield (%)	theor. cont. (%) *	exper. cont. (%) **	spec. rotation
β -cyclodextrin	94.4	16.3	16.2	+133.1° (H ₂ O, 0.29)
methyl- β -cyclodextrin	98.6	14.5	13.5	+133.9° (ethanol abs. 0.30)
hydroxyethyl- β -cyclodextrin	94.5	13.3	13.2	+113.8° (ethanol abs., 0.30)
hydroxypropyl- β -cyclodextrin	97.4	13.8	13.6	+109.2° (ethanol abs., 0.30)
triacetyl- β -cyclodextrin	99.2	9.9	9.8	+113.9° (ethanol abs., 0.30)

* theoretical content of ibuproxam in the complex

** experimentally determined content of ibuproxam in the complex

Example 11

Water solubility

A suspension having the concentration of 200 mg inclusion complex of racemic or optically active S-(+)-ibuproxam in 10 ml water and having pH 5.8 was stirred for 1 hour (500 rpm) at room temperature. Then a sample was filtered through filter paper (blue ribbon) and diluted with absolute ethanol. The concentration of ibuproxam was determined spectrophotometrically at the wavelength of 220 nm and at room temperature.

TABLE 3: Solubility of ibuproxam in water

Solubility of racemic ibuproxam	0.11 mg/ml
inclusion complex of racemic ibuproxam with	solubility (mg/ml)
methyl- β -cyclodextrin	2.8
hydroxyethyl- β -cyclodextrin	2.8
hydroxypropyl- β -cyclodextrin	2.5
triacetyl- β -cyclodextrin	0.4

Solubility of S-(+)-ibuproxam	0.2 (mg/ml)
inclusion complex of S-(+)-ibuproxam with	solubility (mg/ml)
β -cyclodextrin	2.6
methyl- β -cyclodextrin	2.5
hydroxyethyl- β -cyclodextrin	2.5
hydroxypropyl- β -cyclodextrin	2.0
triacetyl- β -cyclodextrin	0.4

As evident from the above data the solubility of ibuproxam is significantly increased by binding its molecule into a cyclodextrin complex. There is no noticeable difference in solubilities of individual hydrophilic derivatives, but the solubility of ibuproxam is greater in the case of hydrophilic derivatives than in the case of hydrophobic derivatives of β -cyclodextrins.

Example 12

Acute toxicity

In toxicological evaluation acute toxicity of S-(+)-ibuprofen, S-(+)-ibuproxam and inclusion complex of S-(+)-ibuproxam with β -cyclodextrin was established. The S-(+)-ibuproxam content in complex was 14.4%. In the test mice of Han-NMRI strain of both sexes, weight 19 to 24 g, and female rats of Han-WISTAR strain, weight 220 to 250 g, were used. The active substance was suspended in arachis oil and applied perorally. The volume of the applied suspension was 0.2 ml/20 g body weight in mice and 0.2 ml/200 g body weight in rats. Before the test the animals were fasted for 24 hours and after application, water and food were available *ad libitum*. The results of testing are summarized in Table 4.

TABLE 4: Acute toxicity of selected substances after peroral application

1. Male mice

Substance	No. of animals in the group	Dosis mg/kg	% of deaths in 24 h	% of deaths after 15 days	LD ₅₀ mg/kg
S-(+)-ibuprofen	10	2000	0	30	> 2000
S-(+)-ibuproxam	10	2000	0	0	> 2000
S-(+)-ibuproxam in inclusion complex with β -cyclodextrin	10	2000	0	0	> 2000

2. Female mice

Substance	No. of animals in the group	Dosis mg/kg	% of deaths in 24 h	% of deaths after 15 days	LD ₅₀ mg/kg
S-(+)-ibuprofen	10	1000	10	10	> 2000
S-(+)-ibuprofen	10	2000	10	10	> 2000
S-(+)-ibuproxam	10	2000	0	0	> 2000
S-(+)-ibuproxam in inclusion complex with β -cyclodextrin	10	1000	0	0	> 2000
	10	2000	0	0	> 2000

3. Female rats

Substance	No. of animals in the group	Dosis mg/kg	% of deaths in 24 h	% of deaths after 15 days	LD ₅₀ mg/kg
S-(+)-ibuprofen	6	1000	0	83.3	< 1000
S-(+)-ibuproxam	6	1000	0	50	\approx 1000
S-(+)-ibuproxam in inclusion complex with β -cyclodextrin	6	2000	0	0	> 2000

It is evident from the above table that acute toxicity of S-(+)-ibuprofen in all test animals is greater than acute toxicity of S-(+)-ibuproxam, irrespective of its being free or bound in the complex with β -cyclodextrin. At the dosis of 2000 mg/kg of S-(+)-ibuprofen 30% of male mice died in 15 days and no animal died at the dosis of

2000 mg/kg of S-(+)-ibuproxam or inclusion complex of S-(+)-ibuproxam with β -cyclodextrin. At the dosis of 2000 mg/kg of S-(+)-ibuprofen 10% of female mice died in 15 days and again no animal died at the dosis of 1000 mg/kg or 2000 mg/kg of S-(+)-ibuproxam or inclusion complex of S-(+)-ibuproxam with β -cyclodextrin.

The difference in acute toxicity between free S-(+)-ibuproxam and S-(+)-ibuproxam bound into inclusion complex with β -cyclodextrin showed in rats which were more susceptible to test substances. At the dosis of 1000 mg/kg of S-(+)-ibuprofen 83.3% of the animals died in 15 days, at the dosis of 1000 mg/kg of S-(+)-ibuproxam 50% of the animals died after 15 days, whereas also at the increased dosis of 2000 mg/kg of S-(+)-ibuproxam bound into inclusion complex with β -cyclodextrin no animal died.

A comparative analysis of the toxicological results for different test animals shows that rats are much more susceptible to ibuprofen than mice, but equally susceptible to ibuproxam as mice. The mean lethal dosis (LD_{50}) for S-(+)-ibuprofen for mice of both sexes is greater than 2000 mg/kg at peroral application, but for female rats it is under 1000 mg/kg. The mean lethal dosis for S-(+)-ibuproxam for mice of both sexes is greater than 2000 mg/kg at peroral application, yet for female rats it is approximately 1000 mg/kg. The mean lethal dose for inclusion complex of S-(+)-ibuproxam with β -cyclodextrin is for mice of both sexes and for female rats greater than 2000 mg/kg.

After peroral application of S-(+)-ibuprofen to male mice in the dosis of 2000 mg/kg, 30% of animals died in 48 hours, whereas in female mice at 1000 mg/kg and at the dosis of 2000 mg/kg 10% of animals died already in the first 24 hours. In female rats after peroral application of ibuprofen in the dosis of 1000 mg/kg, even 83.3% of the animals died in 6 days.

After peroral application of S-(+)-ibuproxam in mice of both sexes at the dosis of 2000 mg/kg, no animal died in 15 days, whereas in female rats at the same dosis 50% of the tested animals died in 15 days.

After peroral application of inclusion complex of S-(+)-ibuproxam no test animal died irrespective of the dosis, which was 1000 mg/kg or 2000 mg/kg.

It is evident from the above data that the inclusion complex of optically active S-(+)-ibuproxam is less toxic than S-(+)-ibuproxam alone, which is in turn less toxic than S-(+)-ibuprofen, which is also the priority aim of the present invention.

Example 13

Antiinflammatory action

Antiinflammatory action was measured *in vivo* by the inhibition of oedema caused by carrageenin.

Rats, which were fasted overnight, were given 100 mg/kg of the test substance 1 hour before the injection of 0.1 ml 1% carrageenin suspension. The inhibition of the formed oedema was measured 3 hours after injecting carrageenin.

TABLE 5: Measurement of antiinflammatory action *in vivo* at the dosis of 100 mg/kg of the active substance applied perorally

Substance	antiinflammatory action
S-(+)-ibuproxam	37
complex of S-(+)-ibuproxam with β -cyclodextrin	75

The measurement *in vivo* of the antiinflammatory action showed that the inclusion complex of S-(+)-ibuproxam with β -cyclodextrin exhibited a twice greater antiinflammatory action than free optically active S-(+)-enantiomer.

It is evident from the above data that the inclusion complex of optically active S-(+)-ibuproxam with β -cyclodextrin showed greater antiinflammatory action than free optically active S-(+)-ibuproxam, which, however, showed greater antiinflammatory action than free racemic ibuproxam, which is also the priority aim of the present invention.

*Example 14***Effect on gastric mucous membrane**

Effect of S-(+)-ibuprofen, S-(+)-ibuproxam and inclusion complex of S-(+)-ibuproxam with β -cyclodextrin on gastric mucous membrane was measured.

Rats, which were fasted overnight, were given perorally 100 mg/kg of the active substance. After 4 hours its effect on irritation of gastric mucous membrane was measured in a way that the rate of bleeding in stomach and frequency of ulcers was determined.

TABLE 6: Measurement of the effect on gastric mucous membrane

Substance	dose (mg/kg)	irritation
S-(+)-ibuprofen	30	12
S-(+)-ibuproxam	30	0
inclusion complex of S-(+)-ibuproxam with β -cyclodextrin	15	0

The above data show that free S-(+)-ibuproxam and S-(+)-ibuproxam bound into an inclusion complex with β -cyclodextrin did not exhibit an irritating effect on gastric mucous membrane of the animals.

*Example 15***Antiinflammatory action and effect on gastric mucous membrane**

Testing antiinflammatory action was carried out according to the method of Winter C.A. et al., Proc. Soc. Exp. Biol. Med., 111 (1962). The effect on gastric mucous membrane was measured in such a way that changes on gastric mucous membrane

were observed under magnifying glass. In the test 120 male rats (Wistar), weight 140 to 170 g, were used.

Animals were fasted 24 hours before the beginning of the test with water *ad libitum*. Active substances to be tested were applied in the dose of 25 mg/kg, 50 mg/kg and 100 mg/kg perorally in the form of a suspension in a 10% gum arabic solution. Control group of rats was given only the vehicle (i.e. the 10% gum arabic solution). After 60 minutes the rats were administered a subcutaneous injection of 0.1 ml of 1.5% carrageenin suspension in 0.9% NaCl solution into a subplantar part of the right hind paw. 0.1 ml of 0.9% NaCl solution only was injected into a subplantar part of the left hind paw as a control. Volumes of both paws were measured by means of plethysmometer (Model 7150, Ugo Basile) immediately and then in intervals of 1 to 5 hours after carrageenin application. The percentage of the swelling of the hind paw was calculated according to the following equation:

% swelling of hind paw =

$$\left(\frac{\text{right paw volume} - \text{starting right paw volume}}{\text{starting right paw volume}} - \frac{\text{left paw volume} - \text{starting left paw volume}}{\text{starting left paw volume}} \right) \cdot 100$$

The testing of the antiinflammatory action was concluded 6 hours after peroral application of the active substance or 5 hours after injecting carrageenin. Then the rats were decapitated and the stomachs were removed and washed with 0.9% NaCl solution. By incision along the lesser bend the stomach was opened and gastric mucous membrane was observed under magnifying glass and possible changes were evaluated according to the following scale (Cashin C.H. et al., J. Pharm. Pharmac. 29 (1977):

- 0 no lesions
- 0.5 hyperaemia
- 1 one or two indistinct lesions
- 1.5 more than two indistinct lesions
- 2 frequent lesions
- 3 very frequent lesions
- 4 lesions are noticeable over the whole gastric mucous membrane

TABLE 7 Therapeutic index: ratio of UD_{50}/ED_{30}

Substance	UD_{50}/ED_{30} (95% confidence limit)
S-(+)-ibuprofen	0.54
racemic ibuproxam	1.37
S-(+)-ibuproxam	1.63
inclusion complex of S-(+)-ibuproxam with β -cyclodextrin	2.21

UD_{50} - calculated dose of the active substance in mg per 1 kg of the animal, which dose caused a change of the gastric mucous membrane at least with the note 1 at 50% animals

ED_{30} - calculated dose of the active substance in mg per 1 kg of the animal, which dose caused a 30% inhibition of carrageenin-induced oedema

It is evident from the above table that the therapeutic index was the most advantageous (the greatest) at the inclusion complex of S-(+)-ibuproxam with β -cyclodextrin since it was four times greater than for S-(+)-ibuprofen, 1.6 times greater than for racemic ibuproxam and 1.4-times greater than for S-(+)-ibuproxam. This means that at the dose of the active substance which caused a 30% inhibition of carrageenin-induced oedema, in the case of the inclusion complex of S-(+)-ibuproxam with β -cyclodextrin a lesser irritation of the gastric mucous membrane occurred in comparison with S-(+)-ibuproxam, which caused a 1.2 times lesser irritation of the gastric mucous membrane in comparison with racemic ibuproxam, which in turn caused a 2.5 times lesser irritation than S-(+)-ibuprofen.

Example 16

Alleviation of pain

The effect of alleviating pain was tested with the number of convulsions caused by phenylbenzoquinone. Female mice, weight 15 to 22 g, were fasted before the test for 24 hours and after the application water and food were *ad libitum*. 30 minutes after peroral introduction of the suspension of active substance in 10% gum arabic solution, individual mice were intraperitoneally administered 0.25 ml of 0.02% phenylbenzoquinone solution. Only the vehicle was applied to a control group of animals. The number of phenylbenzoquinone-induced convulsions was pursued 5 to 20 minutes after the application thereof.

TABLE 8: Measurement of the effect of alleviating pain

Substance	ED ₅₀ (mg/kg) (95% confidence limit)
S-(+)-ibuproxam	73.0
S-(+)-ibuproxam in inclusion complex with β -cyclodextrin	25.0

ED₅₀ - calculated dose of the active substance in mg per 1 kg of the animal, which dose caused a 50% pain protection

It is evident from the above table that ED₅₀ value in the case of S-(+)-ibuproxam bound into the inclusion complex with β -cyclodextrin was even three times lesser than the value for S-(+)-ibuproxam alone, which means that in the case of S-(+)-ibuproxam bound into the inclusion complex with β -cyclodextrin the same effect as with S-(+)-ibuproxam alone could be achieved by a three times lesser dose.

Example 17

X-ray powder diffraction

In Table 9 there are demonstrated lattice spacings d (nm) and intensities (I) of X-ray diffraction for S-(+)-ibuproxam, racemic ibuproxam, β -cyclodextrin, hydroxypropyl- β -cyclodextrin, triacetyl- β -cyclodextrin, for physical mixtures of S-(+)-ibuproxam with β -cyclodextrin, hydroxypropyl- β -cyclodextrin and triacetyl- β -cyclodextrin, for physical mixtures of racemic ibuproxam with hydroxypropyl- β -cyclodextrin and triacetyl- β -cyclodextrin, for inclusion complexes of S-(+)-ibuproxam with β -cyclodextrin, hydroxypropyl- β -cyclodextrin and triacetyl- β -cyclodextrin, and for inclusion complexes of racemic ibuproxam with hydroxypropyl- β -cyclodextrin and triacetyl- β -cyclodextrin. The analysis was made on Philips PW 1710 diffractometer on Al-substrate at the wavelength of $\lambda = 0.15418$ nm (CuK α).

Table 9: Characteristic diffraction maximums

β -cyclodextrin		S-(+)-ibuproxam		physical mixture of S-(+)-ibuproxam + β -cyclodextrin		inclusion complex of S-(+)-ibuproxam + β -cyclodextrin	
d(nm)	I	d(nm)	I	d(nm)	I	d(nm)	I
0.701	75	0.383	52	0.699	72	0.508	68
0.687	100	0.380	53	0.493	74	0.502	91
0.657	53	0.369	100	0.471	65	0.497	100
0.495	51	0.354	45	0.467	88	0.489	78
0.487	68	0.264	46	0.418	79	0.477	72
0.472	55	0.237	51	0.392	95	0.472	81
		0.205	50	0.387	99	0.468	83
				0.327	73	0.368	59
				0.257	100	0.236	67
				0.204	92	0.204	84

hydroxypropyl- β -cyclodextrin		S-(+)-ibuproxam		physical mixture of S-(+)-ibuproxam + hydroxypropyl- β -cyclodextrin		inclusion complex of S-(+)-ibuproxam + hydroxypropyl- β -cyclodextrin	
d(nm)	I	d(nm)	I	d(nm)	I	d(nm)	I
0.500	86	0.383	52	0.493	80	0.488	92
0.490	89	0.380	53	0.478	81	0.469	91
0.486	89	0.369	100	0.467	89	0.458	87
0.470	100	0.354	45	0.456	86	0.458	92
0.454	88	0.264	46	0.442	84	0.448	81
		0.237	51	0.205	100	0.204	100
		0.205	50				

triacetyl- β -cyclodextrin		S-(+)-ibuproxam		physical mixture of S-(+)-ibuproxam + triacetyl- β -cyclodextrin		inclusion complex of S-(+)-ibuproxam + triacetyl- β -cyclodextrin	
d(nm)	I	d(nm)	I	d(nm)	I	d(nm)	I
0.470	68	0.383	52	0.474	92	0.416	78
0.441	72	0.380	53	0.468	98	0.408	78
0.438	61	0.369	100	0.445	99	0.399	84
0.401	68	0.354	45	0.403	90	0.385	80
0.204	100	0.264	46	0.387	100	0.390	78
		0.237	51	0.385	85	0.204	100
		0.205	50				

hydroxypropyl- β -cyclodextrin		racemic ibuproxam		physical mixture of racemic ibuproxam + hydroxypropyl- β -cyclodextrin		inclusion complex of racemic ibuproxam + hydroxypropyl- β -cyclodextrin	
d(nm)	I	d(nm)	I	d(nm)	I	d(nm)	I
0.500	86	1.225	95	0.480	82	0.480	80
0.490	89	1.133	74	0.473	92	0.464	80
0.486	89	0.634	43	0.468	100	0.457	79
0.470	100	0.471	83	0.462	89	0.448	79
0.454	88	0.382	100	0.382	87	0.204	100

triacetyl- β -cyclodextrin		racemic ibuproxam		physical mixture of racemic ibuproxam + triacetyl- β -cyclodextrin		inclusion complex of racemic ibuproxam + triacetyl- β -cyclodextrin	
d(nm)	I	d(nm)	I	d(nm)	I	d(nm)	I
0.470	68	1.225	95	0.473	94	0.424	80
0.441	72	1.133	74	0.464	89	0.407	79
0.438	61	0.634	43	0.438	100	0.404	79
0.401	68	0.471	83	0.402	94	0.394	80
0.204	100	0.382	100	0.388	88	0.204	100

Figs. 22A to 22D show the comparison of recordings of X-ray powder diffraction for β -cyclodextrin (Fig. 22A), S-(+)-ibuproxam (Fig. 22B), physical mixture of S-(+)-ibuproxam and β -cyclodextrin (Fig. 22C) and inclusion complex of S-(+)-ibuproxam with β -cyclodextrin (Fig. 22D).

Figs. 23A to 23D show the comparison of recordings of X-ray powder diffraction for hydroxypropyl- β -cyclodextrin (Fig. 23A), S-(+)-ibuproxam (Fig. 23B), physical mixture of S-(+)-ibuproxam and hydroxypropyl- β -cyclodextrin (Fig. 23C) and inclusion complex of S-(+)-ibuproxam with hydroxypropyl- β -cyclodextrin (Fig. 23D).

Figs. 24A to 24D show the comparison of recordings of X-ray powder diffraction for triacetyl- β -cyclodextrin (Fig. 24A), S-(+)-ibuproxam (Fig. 24B), physical mixture of S-(+)-ibuproxam and triacetyl- β -cyclodextrin (Fig. 24C) and inclusion complex of S-(+)-ibuproxam with triacetyl- β -cyclodextrin (Fig. 24D).

Figs. 25A to 25D show the comparison of recordings of X-ray powder diffraction for hydroxypropyl- β -cyclodextrin (Fig. 25A), racemic ibuproxam (Fig. 25B), physical mixture of racemic ibuproxam and hydroxypropyl- β -cyclodextrin (Fig. 25C) and inclusion complex of racemic ibuproxam with hydroxypropyl- β -cyclodextrin (Fig. 25D).

Figs. 26A to 26D show the comparison of recordings of X-ray powder diffraction for triacetyl- β -cyclodextrin (Fig. 26A), racemic ibuproxam (Fig. 26B), physical mixture of racemic ibuproxam and triacetyl- β -cyclodextrin (Fig. 26C) and inclusion complex of racemic ibuproxam with triacetyl- β -cyclodextrin (Fig. 26D).

Example 18

Preparation of tablets with 200 mg of active substance (inclusion complex of S-(+)-ibuproxam with β -cyclodextrin)

Tablets of the following composition were prepared:

inclusion complex of S-(+)-ibuproxam	
with β -cyclodextrin	1300.0 mg
polivinylpyrrolidone	5.0 mg
crospovidone (cross-linked polyvinylpyrrolidone)	96.0 mg
colloidal silicon dioxide	3.2 mg

stearic acid	16.0 mg
microcrystalline cellulose	ad1600.0 mg

Preparation of tablets:

The active substance was homogeneously stirred with additives. The mixture was sieved through a sieve and pressed into tablets on a rotating tableting machine.

Example 19

Preparation of dispersion tablets with 200 mg of active substance (inclusion complex of S-(+)-ibuproxam with β -cyclodextrin)

Dispersion tablets of the following composition were prepared:

inclusion complex of S-(+)-ibuproxam

with β -cyclodextrin

1300.0 mg

low substituted hydroxypropyl cellulose

100.0 mg

saccharin

2.0 mg

flavours

10.0 mg

coloidal silicon dioxide

1.6 mg

stearic acid

16.5 mg

microcrystalline cellulose

ad1650.0 mg

The preparation of dispersion tablets:

The active component was homogeneously blended with additives. The mixture was sieved through a sieve and pressed into tablets on a rotating tableting machine. The tablets rapidly disintegrated in water, the obtained suspension had a pleasant taste and was appropriate for consumption.

Example 20

Preparation of tablets with 200 mg of active substance (S-(+)-ibuproxam)

Tablets of the following composition were prepared:


S-(+)-ibuproxam	200.0 mg
maize starch	22.0 mg
crospovidone (Polyplasdone ® XL)	16.2 mg
povidone	16.2 mg
colloidal silicon dioxide (Aerosil 200)	1.4 mg
talcum	9.7 mg
stearic acid	6.5 mg
microcrystalline cellulose	ad 325.0 mg

Preparation of tablets:

The active component was homogeneously stirred with a part of the ingredients (maize starch, crospovidone, microcrystalline cellulose) and granulated with polyvinylpyrrolidone aqueous solution. The obtained granulate was dried, sieved, blended with the remaining amount of the additives (colloidal silicon dioxide, talcum, stearic acid) and pressed into tablets on a rotating tableting machine.

CLAIMS

1. Inclusion complexes of racemic 2-(4-isobutylphenyl)-propiohydroxamic acid and optically active S-(+)-2-(4-isobutylphenyl)-propiohydroxamic acid (ibuproxam) of the formula



with cyclodextrin derivatives and, in the case of optically active S-(+)-2-(4-isobutylphenyl)-propiohydroxamic acid, also with β -cyclodextrin alone.

2. Inclusion complexes according to claim 1, characterized in that the cyclodextrin derivative is selected from methyl- β -cyclodextrin, dimethyl- β -cyclodextrin, hydroxyethyl- β -cyclodextrin, hydroxypropyl- β -cyclodextrin and triacetyl- β -cyclodextrin.
3. Inclusion complex of optically active S-(+)-ibuproxam with β -cyclodextrin.
4. Inclusion complex of optically active S-(+)-ibuproxam with hydroxyethyl- β -cyclodextrin.
5. Inclusion complex of optically active S-(+)-ibuproxam with hydroxypropyl- β -cyclodextrin.
6. Inclusion complex of optically active S-(+)-ibuproxam with dimethyl- β -cyclodextrin.
7. Inclusion complex of optically active S-(+)-ibuproxam with methyl- β -cyclodextrin.
8. Inclusion complex of optically active S-(+)-ibuproxam with triacetyl- β -cyclodextrin.

9. Inclusion complex of racemic ibuproxam with hydroxyethyl- β -cyclodextrin.
10. Inclusion complex of racemic ibuproxam with hydroxypropyl- β -cyclodextrin.
11. Inclusion complex of racemic ibuproxam with dimethyl- β -cyclodextrin.
12. Inclusion complex of racemic ibuproxam with methyl- β -cyclodextrin.
13. Inclusion complex of racemic ibuproxam with triacetyl- β -cyclodextrin.
14. Inclusion complexes according to claims 1 to 13, characterized in that the molar ratio between racemic ibuproxam or optically active S-(+)-ibuproxam and cyclodextrin derivative or, in the case of optically active S-(+)-ibuproxam, with β -cyclodextrin amounts to 1:5 to 5:1.
15. Inclusion complexes according to claim 14, characterized in that the molar ratio between racemic ibuproxam or optically active S-(+)-ibuproxam and cyclodextrin derivative or, in the case of optically active S-(+)-ibuproxam, with β -cyclodextrin amounts to 1:2 to 2:1.
16. Process for preparing inclusion complexes of racemic ibuproxam and of optically active S-(+)-ibuproxam with hydrophilic derivatives of β -cyclodextrin, characterized in that either
 - a) racemic ibuproxam or its S-(+)-enantiomer is at room temperature added to a methanolic solution of hydrophilic derivative of β -cyclodextrin and the desired inclusion complex is isolated; or
 - b) a hydrophilic derivative of β -cyclodextrin is dissolved in water, the solution is heated to a temperature of about 70 °C, racemic ibuproxam or its S-(+)-enantiomer is added, it is vigorously stirred and the obtained solution is frozen in liquid nitrogen and lyophilized.
17. Process for preparing inclusion complexes of racemic ibuproxam and of optically active S-(+)-ibuproxam with hydrophobic derivatives of β -cyclodextrin, characterized in that either
 - a) a hydrophobic derivative of β -cyclodextrin is dissolved in an organic solvent and then a racemic ibuproxam or optically active S-(+)-ibuproxam is added while stirring at room temperature, the obtained clear solution is evaporated *in vacuo* at

the temperature of 40 °C and the residue is dried *in vacuo* at room temperature to the desired product; or

b) a hydrophobic derivative of β -cyclodextrin is dissolved in an organic solvent at a temperature of 20 to 60 °C and then there are added racemic ibuproxam or optically active S-(+)-ibuproxam and also water under vigorous stirring, the obtained solution is cooled to a temperature between 0 and 5 °C and the formed desired compound is filtered off and dried *in vacuo* at a temperature of about 40 °C.

18. Process for preparing optically active S-(+)-ibuproxam, characterized in that S-(+)-ibuprofen is reacted in methanol into S-(+)-ibuprofen methyl ester at a temperature of 10 to 50 °C and then it is reacted at a temperature of 0 to 50 °C with hydroxylamine hydrochloride in a lower alcohol with 1 to 4 carbon atoms such as methanol into the desired compound.

19. Process for preparing optically active S-(+)-ibuproxam, characterized in that S-(+)-ibuprofen is reacted in an organic solvent into S-(+)-ibuprofen anhydride at a temperature of 10 to 50 °C and then it is reacted at room temperature with hydroxylamine in an organic solvent such as dichloromethane into the desired compound.

20. Pharmaceutical preparations for the treatment of inflammations and febrile conditions and for alleviating pain, characterized in that they contain a therapeutically active amount of the optically active S-(+)-ibuproxam together with a conventional pharmaceutically acceptable carrier and other adjuvants.

21. Pharmaceutical preparations for the treatment of inflammations and febrile conditions and for alleviating pain, characterized in that they contain a therapeutically active amount of inclusion complex of racemic ibuproxam or optically active S-(+)-ibuproxam with cyclodextrin derivatives and, in the case of optically active S-(+)-ibuproxam, also with β -cyclodextrin alone, together with a conventional pharmaceutically acceptable carrier and other adjuvants.

22. Pharmaceutical preparations for the treatment of inflammations and febrile conditions and for alleviating pain, characterized in that they contain a therapeutically active amount of inclusion complex of racemic ibuproxam or optically active S-(+)-ibuproxam with β -cyclodextrin derivative selected from hydroxyethyl- β -

cyclodextrin, hydroxypropyl- β -cyclodextrin, dimethyl- β -cyclodextrin, methyl- β -cyclodextrin and triacetyl- β -cyclodextrin.

23. Pharmaceutical preparations for the treatment of inflammations and febrile conditions and for alleviating pain, characterized in that they contain a therapeutically active amount of inclusion complex of optically active S-(+)-ibuproxam with β -cyclodextrin.

24. Use of optically active S-(+)-ibuproxam in the treatment of inflammations and febrile conditions and for alleviating pain.

25. Use of inclusion complexes of racemic ibuproxam or optically active S-(+)-ibuproxam with cyclodextrin derivatives and, in the case of optically active S-(+)-ibuproxam, with β -cyclodextrin alone in the treatment of inflammations and febrile conditions and for alleviating pain.

26. Use of inclusion complexes of racemic ibuproxam or optically active S-(+)-ibuproxam with a β -cyclodextrin derivative selected from hydroxyethyl- β -cyclodextrin, hydroxypropyl- β -cyclodextrin, dimethyl- β -cyclodextrin, methyl- β -cyclodextrin and triacetyl- β -cyclodextrin, in the treatment of inflammations and febrile conditions and for alleviating pain.

27. Use of optically active S-(+)-ibuproxam for preparing a medicine for the treatment of inflammations and febrile conditions and for alleviating pain.



28. Use of inclusion complexes of racemic ibuproxam or optically active S-(+)-ibuproxam with cyclodextrin derivatives and, in the case of optically active S-(+)-ibuproxam, with β -cyclodextrin alone for preparing a medicine for the treatment of inflammations and febrile conditions and for alleviating pain.

29. Use of inclusion complexes of racemic ibuproxam or optically active S-(+)-ibuproxam with a β -cyclodextrin derivative selected from hydroxyethyl- β -cyclodextrin, hydroxypropyl- β -cyclodextrin, dimethyl- β -cyclodextrin, methyl- β -cyclodextrin and triacetyl- β -cyclodextrin, for preparing a medicine for the treatment of inflammations and febrile conditions and for alleviating pain.

30. Optically active S-(+)-ibuproxam for use in the treatment of inflammations and febrile conditions and for alleviating pain.
31. Inclusion complexes of racemic ibuproxam or optically active S-(+)-ibuproxam with cyclodextrin derivatives and, in case of optically active S-(+)-ibuproxam, with β -cyclodextrin alone for use in the treatment of inflammations and febrile conditions and for alleviating pain.
32. Inclusion complexes of racemic ibuproxam or optically active S-(+)-ibuproxam with a β -cyclodextrin derivative selected from hydroxyethyl- β -cyclodextrin, hydroxypropyl- β -cyclodextrin, dimethyl- β -cyclodextrin, methyl- β -cyclodextrin and triacetyl- β -cyclodextrin, for use in the treatment of inflammations and febrile conditions and for alleviating pain.

1/51

Fig. 1



2/51





Fig. 2A



RACEMIC IBUPROXAM

3/51

Fig. 2B


S-(+)-IBUPROXAM



4/51
Fig. 3

5/51


Fig. 4A



PHYSICAL MIXTURE


6/51

Fig. 4B




INCLUSION COMPLEX

Fig. 5



8/51


Fig. 6A



PHYSICAL MIXTURE

9/51


Fig. 6B



INCLUSION COMPLEX


10/51

Fig. 7



11/51


Fig. 8A



PHYSICAL MIXTURE


12/51

Fig. 8B



INCLUSION COMPLEX


13/51



६९

14/51


Fig. 10A



PHYSICAL MIXTURE


15/51

Fig. 10B




INCLUSION COMPLEX

Fig. 11



17/51


Fig. 12A



PHYSICAL MIXTURE

18/51


Fig.12B



INCLUSION COMPLEX


19/51

Fig. 13



20/51


Fig. 14A



PHYSICAL MIXTURE


21/51

Fig. 14 B




INCLUSION COMPLEX

Fig. 15



23/51


Fig. 16A



PHYSICAL MIXTURE


24/51

Fig. 16B




INCLUSION COMPLEX

Fig. 17



26/51


Fig. 18A



PHYSICAL MIXTURE

27/51

Fig. 18B



INCLUSION COMPLEX

28/51





Fig. 19

29/51

Fig. 20A



PHYSICAL MIXTURE

30/51

Fig. 20B






Fig. 21




32/51

Fig. 22A




33/51

Fig. 22B




34/51

Fig. 22C




35/51

Fig. 220




36/51

Fig. 23A




37/51

Fig. 23B




38/51

Fig. 23C




39/51

Fig. 23D




40/51

Fig. 24A




41/51

Fig. 24B




42/51

Fig. 24C



43/51

Fig. 24D



44/51

Fig. 25A






Fig. 25B




46/51

Fig. 25C



47/51

Fig. 25D



48/51

Fig. 26A






Fig. 26B




50 / 51

Fig. 26C



51/51

Fig. 260



A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/185 A61K47/48 C07C259/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP, A, 0 268 215 (LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, N.SOL.O) 25 May 1988 cited in the application see the whole document ---	1-17, 21-23, 25,26, 28,29, 31,32
Y	ACTA PHARM., vol.42, no.1, 1992, ZAGREB pages 85 - 90 J. ZMITEK ET AL. 'Inclusion complex of ibuprofex with beta-cyclodextrin' see the whole document ---	1-17, 21-23 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

7

Date of the actual completion of the international search

11 January 1995

Date of mailing of the international search report

27.01.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Foerster, W

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document with indication, where appropriate, of the relevant passages	Relevant to claim No.*
Y	ACTA PHARM. TECHNOL., vol.34, no.1, 1988 pages 17 - 21 G. MAZZI ET AL. 'Formation of inclusion complex between the non-steroidal anti-inflammatory drug (RS)-2-(4-isobutyl phenyl)-propiohydroxamic acid and beta cyclodextrin' see the whole document ---	1-17, 21-23
Y	WO,A,92 09308 (MEDICE CHEM. PHARM. FABRIK PUTTER GMBH & CO. KG) 11 June 1992 cited in the application see page 2, last paragraph - page 6, last paragraph ---	1-17, 21-23, 25,26, 28,29, 31,32
Y	EP,A,0 274 444 (BRISTOL-MEYERS CO.) 13 July 1988 ---	1-17, 21-23
Y	INT. J. PHARM., vol.90, no.1, January 1993 N. MULINACCI ET AL. 'Molecular modelling and NMR NOE experiments: Complementary tools for the investigation of complex ibuprofam-beta-cyclodextrin topology' see figures 1,3; tables 1,3 ---	1-17, 21-23, 31,32
Y	BIOCHIM. BIOPHYS. ACTA, vol.1078, no.3, 1991 pages 411 - 417 C-S. CHEN ET AL. 'Metabolic stereoisomeric inversion of ibuprofen in mammals' see page 412, right column, paragraph 1; figure 1 ---	18-20, 24,27,30
Y	US,A,4 082 707 (G. ORZALESI) 4 April 1978 cited in the application see column 1, line 36 - column 2, line 13 ---	18-20, 24,27,30
Y	EP,A,0 203 379 (LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, N.SOL.O) 3 December 1986 see page 2; claims 1,2 ---	18-20, 24,27,30
Y	WO,A,92 20334 (THE BOOTS COMPANY PLC.) 26 November 1992 cited in the application see the whole document ---	18-20, 24,27,30
7 1 A	EP,A,0 295 476 (EDMOND PHARMA S.R.L.) 21 December 1988 see page 1, line 15 - page 1, line 36; examples 1-11 -----	16,17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/ASI 94/00015

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0268215	25-05-88	AU-B-	605517	17-01-91
		AU-A-	8117387	19-05-88
		DE-D-	3787703	11-11-93
		JP-A-	63183546	28-07-88
		US-A-	4952565	28-08-90
WO-A-9209308	11-06-92	DE-A-	4038314	04-06-92
		AU-A-	8951791	25-06-92
		EP-A-	0490193	17-06-92
EP-A-0274444	13-07-88	AU-B-	609441	02-05-91
		AU-A-	1004588	14-07-88
		CA-A-	1298290	31-03-92
		JP-A-	63190824	08-08-88
		ZA-A-	8800088	11-07-88
US-A-4082707	04-04-78	BE-A-	809524	02-05-74
		DE-A-	2400531	25-07-74
		FR-A, B	2213062	02-08-74
		GB-A-	1447658	25-08-76
		JP-C-	952797	25-05-79
		JP-A-	50005351	21-01-75
		JP-B-	53031140	31-08-78
EP-A-0203379	03-12-86	JP-A-	61263950	21-11-86
WO-A-9220334	26-11-92	AU-A-	1671192	30-12-92
		BG-A-	98214	15-07-94
		CA-A-	2102530	14-11-92
		CN-A-	1068734	10-02-93
		CZ-A-	9302405	16-03-94
		EP-A-	0584108	02-03-94
		JP-T-	6507159	11-08-94
		NO-A-	934102	12-11-93
EP-A-0295476	21-12-88	DE-A-	3867718	27-02-92
		JP-A-	1093587	12-04-89
		US-A-	5010064	23-04-91

THIS PAGE BLANK (USPTO)